Lucid Diagnostics Inc. (LUCD)

1.2800 +0.0600 (+4.92%) At close: 04:00PM EST

Lucid Diagnostics Inc.

One Grand Central Place
Suite 4600
New York, NY 10165
United States
212 949 4319
https://www.luciddx.com

Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Lishan Aklog M.D.	Chairman & CEO	N/A	N/A	1966
Mr. Dennis M. McGrath CPA	CFO, Pres & Sec.	N/A	N/A	1957
Dr. Sanford D. Markowitz M.D., Ph.D.	Cofounder & Strategic Advisor, Member of the Medical Advisor Board	14.54k	N/A	N/A
Dr. Joseph Willis M.D.	Cofounder, Strategic Advisor & Member of Medical Advisory Board	N/A	N/A	N/A
Dr. Amitabh Chak M.D.	Cofounder, Strategic Advisor & Member of Medical Advisory Board	N/A	N/A	N/A
Mr. Shaun M. O'Neill M.B.A.	Exec. VP & COO	N/A	N/A	1982
Richard D. Yazbeck	Chief Technology Officer	N/A	N/A	N/A
Dr. Suman M. Verma M.D., Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Adrian K. Miller	VP of Investor Relations	N/A	N/A	N/A
Dr. Brian J. deGuzman M.D.	Chief Compliance Officer	N/A	N/A	1965

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Corporate Governance

Lucid Diagnostics Inc.’s ISS Governance QualityScore as of January 28, 2023 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.